RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2023 May 1

PMID 37123985

Authors

Sara Boyce

Savita Rangarajan

Affiliations

Soon will be listed here.

Abstract

Severe hemophilia is associated with spontaneous, prolonged and recurrent bleeding. Inadequate prevention and treatment of bleeding can lead to serious morbidity and mortality. Due to the limitations of intravenous clotting factor replacement, including the risk of inhibitory antibodies, innovative novel therapies have been developed that have dramatically changed the landscape of hemophilia therapy. Ribonucleic acid interference (RNAi) has brought the opportunity for multiple strategies to manipulate the hemostatic system and ameliorate the bleeding phenotype in severe bleeding disorders. Fitusiran is a RNAi therapeutic that inhibits the expression of the natural anticoagulant serpin antithrombin. Reduction in antithrombin is known to cause thrombosis if coagulation parameters are otherwise normal and can rebalance hemostasis in severe hemophilia. Reports from late stage clinical trials of fitusiran in hemophilia A and B participants, with and without inhibitory antibodies to exogenous clotting factor, have demonstrated efficacy in preventing bleeding events showing promise for a future "universal" prophylactic treatment of individuals with moderate-severe hemophilia.

Citing Articles

Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review.

El-Sayed A, Bolous N Pharmacoecon Open. 2024; 9(2):179-205.

PMID: 39548037 PMC: 11865401. DOI: 10.1007/s41669-024-00540-4.

Ckip-1 3'UTR alleviates prolonged sleep deprivation induced cardiac dysfunction by activating CaMKK2/AMPK/cTNI pathway.

Dong B, Xue R, Li J, Ling S, Xing W, Liu Z Mol Biomed. 2024; 5(1):23.

PMID: 38871861 PMC: 11176284. DOI: 10.1186/s43556-024-00186-y.

The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature.

Huang H, Badar S, Said M, Shah S, Bharadwaj H, Ramamoorthy K Mol Biol Rep. 2024; 51(1):493.

PMID: 38580818 DOI: 10.1007/s11033-024-09457-x.

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?.

Thau H, Neuber S, Emmert M, Nazari-Shafti T Cardiol Ther. 2024; 13(1):39-67.

PMID: 38381282 PMC: 10899152. DOI: 10.1007/s40119-024-00353-w.

Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy.

Ullah Khan S, Khan M, Suleman M, Inam A, Azhar Ud Din M Curr Gene Ther. 2024; 24(4):265-277.

PMID: 38284735 DOI: 10.2174/0115665232279893231228065540.

References

Andersson N, Auerswald G, Barnes C, Carcao M, Dunn A, Fijnvandraat K . Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 2017; 179(2):298-307. DOI: 10.1111/bjh.14844. View

Barakat M, Kaiser P . VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009; 18(5):637-46. DOI: 10.1517/13543780902855316. View

Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet J . Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005; 93(3):475-80. DOI: 10.1160/TH04-10-0706. View

Polderdijk S, Adams T, Ivanciu L, Camire R, Baglin T, Huntington J . Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood. 2016; 129(1):105-113. PMC: 5305054. DOI: 10.1182/blood-2016-05-718635. View

Pierce G, Haffar A, Ampartzidis G, Peyvandi F, Diop S, El-Ekiaby M . First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia. 2018; 24(2):229-235. DOI: 10.1111/hae.13409. View

Aymonnier K, Kawecki C, Venisse L, Boulaftali Y, Christophe O, Lenting P . Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. Blood. 2019; 134(19):1632-1644. PMC: 9635585. DOI: 10.1182/blood.2019000281. View

Safdar H, Cheung K, Vos H, Gonzalez F, Reitsma P, Inoue Y . Modulation of mouse coagulation gene transcription following acute in vivo delivery of synthetic small interfering RNAs targeting HNF4α and C/EBPα. PLoS One. 2012; 7(6):e38104. PMC: 3365905. DOI: 10.1371/journal.pone.0038104. View

Ridker P, Miletich J, Hennekens C, Buring J . Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277(16):1305-7. View

Male C, Andersson N, Rafowicz A, Liesner R, Kurnik K, Fischer K . Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2020; 106(1):123-129. PMC: 7776246. DOI: 10.3324/haematol.2019.239160. View

10.

Hoffman M, Monroe D . Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007; 21(1):1-11. DOI: 10.1016/j.hoc.2006.11.004. View

11.

Chowdary P . Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. Drugs. 2018; 78(9):881-890. PMC: 6013504. DOI: 10.1007/s40265-018-0922-6. View

12.

Livnat T, Sehgal A, Qian K, Van Nguyen H, Madigan K, Sorensen B . Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction. Blood Cells Mol Dis. 2020; 82:102416. DOI: 10.1016/j.bcmd.2020.102416. View

13.

Springer A, Dowdy S . GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018; 28(3):109-118. PMC: 5994659. DOI: 10.1089/nat.2018.0736. View

14.

Rau J, Mitchell J, Fortenberry Y, Church F . Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost. 2011; 37(4):339-48. DOI: 10.1055/s-0031-1276582. View

15.

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe S . WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6:1-158. DOI: 10.1111/hae.14046. View

16.

Kempton C, Makris M, Holme P . Management of comorbidities in haemophilia. Haemophilia. 2020; 27 Suppl 3:37-45. DOI: 10.1111/hae.14013. View

17.

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

18.

Escuriola Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R . Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost. 2001; 85(2):218-20. View

19.

Barbon E, Ayme G, Mohamadi A, Ottavi J, Kawecki C, Casari C . Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Mol Med. 2020; 12(4):e11298. PMC: 7136963. DOI: 10.15252/emmm.201911298. View

20.

Weng Y, Xiao H, Zhang J, Liang X, Huang Y . RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019; 37(5):801-825. DOI: 10.1016/j.biotechadv.2019.04.012. View